In this phase 2, randomized, placebo-controlled study in individuals with sHTG (fasting serum triglycerides >500 mg dl−1 at screening; medical history of fasting triglycerides ≥1,000 mg dl−1) and with a history of hospitalization for AP, the prespecified primary end point of percent change in mean triglycerides was not met; however, triglycerides were not normally distributed and a post hoc analysis of the median percent change in triglycerides suggested triglyceride reduction with evinacumab, except in those patients with FCS due to LPL deficiency. This evidence concerns the gene LPL and hyperinsulinemic hypoglycemia, familial, 4.